Immunogenic peptides of the cyclin B1 tumor antigen
US10550166B2 · kind B2 · utility
0Cited by
0References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 12, 2017 |
| Grant date | Feb 4, 2020 |
| Priority date | — |
| Expiry date | Sep 12, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K39/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to peptides comprising at least one CD4+ T epitope, which is immunodominant in vitro, of the cyclin B1 tumor antigen, said peptides being capable of stimulating a specific human CD4+ T lymphocyte response in subjects who have varied HLA II molecules, and to the use of these peptides as a cancer vaccine and as a reagent for the diagnosis of cancer or the immunomonitoring of the cellular response against cyclin B1 during cancer or during an anticancer treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.